Patent 10918676 was granted and assigned to Aimmune Therapeutics on February, 2021 by the United States Patent and Trademark Office.
The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies.